Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy.

  title={Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy.},
  author={Tetsuya Shinozaki and Hideomi Watanabe and Takashi Yanagawa and Kenji Shirakura and Kenji Takagishi},
  journal={The Annals of pharmacotherapy},
  volume={36 6},
OBJECTIVE To conduct a retrospective evaluation of tetrahydropyranyladriamycin (PIR)-based combination chemotherapy for osteosarcomas in comparison with doxorubicin (DOX)-based regimens to determine differences in response and toxicities between DOX- and PIR-containing regimens. METHODS Toxicities and response rates of the 2 anthracyclines given as combination chemotherapy were assessed in patients with osteosarcoma, with 19 patients receiving PIR-based and 11 receiving DOX-based regimens… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…